Combs Andrew 4
4 · Prelude Therapeutics Inc · Filed Dec 15, 2021
Insider Transaction Report
Form 4
Combs Andrew
Chief Chemistry Officer
Transactions
- Purchase
Common Stock
2021-12-13$12.12/sh+4,000$48,480→ 264,380 total - Purchase
Common Stock
2021-12-14$11.60/sh+4,000$46,400→ 268,380 total
Footnotes (1)
- [F1]Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met.